TowerView LLC’s Corvus Pharmaceuticals CRVS Stock Holding History

TowerView LLC’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.02M	Sell	70,000 -70,000	-50%	-$1.12M	0.66%	12
2025 Q4	$1.08M	Sell	140,000 -30,000	-18%	-$237K	0.78%	12
2025 Q3	$1.25M	Hold	170,000	–	–	0.91%	13
2025 Q2	$680K	Buy	170,000 +42,500	+33%	+$155K	0.48%	15
2025 Q1	$405K	Buy	127,500 +50,000	+65%	+$236K	0.29%	21
2024 Q4	$415K	Sell	77,500 -40,000	-34%	-$299K	0.3%	19
2024 Q3	$620K	Sell	117,500 -282,500	-71%	-$1.01M	0.4%	17
2024 Q2	$728K	Buy	400,000 +17,500	+5%	+$32.6K	0.48%	17
2024 Q1	$681K	Sell	382,500 -54,373	-12%	-$114K	0.45%	16
2023 Q4	$769K	Buy	436,873 +94,395	+28%	+$138K	0.47%	17
2023 Q3	$500K	Buy	342,478 +137,478	+67%	+$291K	0.33%	18
2023 Q2	$469K	Buy	+205,000	New	+$426K	0.31%	19

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TowerView LLC's CRVS Position: Q1 2026 in Review

TowerView LLC reduced its Corvus Pharmaceuticals (CRVS) stake by 50% in Q1 2026, selling an estimated $1.12M and leaving 70,000 shares worth $1.02M. The position accounts for 0.66% of the portfolio, ranked #12.

TowerView LLC first reported a position in CRVS in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.25M in Q3 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

TowerView LLC held 70,000 shares of Corvus Pharmaceuticals worth $1.02M as of Q1 2026.
TowerView LLC sold 70,000 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.12M.
Corvus Pharmaceuticals made up 0.66% of TowerView LLC's portfolio in Q1 2026, its #12 holding.
TowerView LLC first reported a position in Corvus Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
TowerView LLC's Corvus Pharmaceuticals position peaked at $1.25M in Q3 2025.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on TowerView LLC's 13F filing for Q1 2026, filed 5 May 2026.